Literature DB >> 19465938

Inhibition of the Wnt/beta-catenin pathway by the WWOX tumor suppressor protein.

N Bouteille1, K Driouch, P El Hage, S Sin, E Formstecher, J Camonis, R Lidereau, F Lallemand.   

Abstract

The WWOX gene encodes a candidate tumor suppressor protein (WWOX) implicated in a variety of human diseases such as cancer. To better understand the molecular mechanisms of WWOX action, we investigated novel partners of this protein. Using the two-hybrid system and a coimmunoprecipitation assay, we observed a physical association between WWOX and the Dishevelled protein (Dvl) family signaling elements involved in the Wnt/beta-catenin pathway. We found that enforced WWOX expression inhibited, and inhibition of endogenous WWOX expression stimulated the transcriptional activity of the Wnt/beta-catenin pathway. Inhibition of endogenous WWOX expression also enhanced the effect of Wnt-3a on beta-catenin stability. Moreover, we observed the sequestration of Dvl-2 wild type and Dvl-2NESm, a mutated form of Dvl-2 predominantly localized in the nucleus, in the cytoplasm compartment by WWOX. Our results indicate that WWOX is a novel inhibitor of the Wnt/beta-catenin pathway. WWOX would act, at least in part, by preventing the nuclear import of the Dvl proteins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19465938     DOI: 10.1038/onc.2009.120

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  53 in total

1.  Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease.

Authors:  Juliette D Godin; Ghislaine Poizat; Miriam A Hickey; Florence Maschat; Sandrine Humbert
Journal:  EMBO J       Date:  2010-06-08       Impact factor: 11.598

2.  A multi-exon deletion within WWOX is associated with a 46,XY disorder of sex development.

Authors:  Stefan White; Jacqueline Hewitt; Erin Turbitt; Yvonne van der Zwan; Remko Hersmus; Stenvert Drop; Peter Koopman; Vincent Harley; Martine Cools; Leendert Looijenga; Andrew Sinclair
Journal:  Eur J Hum Genet       Date:  2011-11-09       Impact factor: 4.246

Review 3.  Phosphorylation/de-phosphorylation in specific sites of tumor suppressor WWOX and control of distinct biological events.

Authors:  Shenq-Shyang Huang; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-08

Review 4.  Atypical regulators of Wnt/β-catenin signaling as potential therapeutic targets in Hepatocellular Carcinoma.

Authors:  Jianxiang Chen; Muthukumar Rajasekaran; Kam M Hui
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-21

5.  Genome-wide association study of bipolar disorder accounting for effect of body mass index identifies a new risk allele in TCF7L2.

Authors:  S J Winham; A B Cuellar-Barboza; A Oliveros; S L McElroy; S Crow; C Colby; D-S Choi; M Chauhan; M Frye; J M Biernacka
Journal:  Mol Psychiatry       Date:  2013-12-10       Impact factor: 15.992

6.  Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks.

Authors:  Mohammad Abu-Odeh; Tomer Bar-Mag; Haiming Huang; TaeHyung Kim; Zaidoun Salah; Suhaib K Abdeen; Marius Sudol; Dana Reichmann; Sachdev Sidhu; Philip M Kim; Rami I Aqeilan
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

Review 7.  Strategies of oncogenic microbes to deal with WW domain-containing oxidoreductase.

Authors:  Yao Chang; Yu-Yan Lan; Jenn-Ren Hsiao; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2014-12-07

Review 8.  WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies.

Authors:  C Marcelo Aldaz; Brent W Ferguson; Martin C Abba
Journal:  Biochim Biophys Acta       Date:  2014-06-14

Review 9.  Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers.

Authors:  H Wang; L Liang; J-Y Fang; J Xu
Journal:  Oncogene       Date:  2015-08-10       Impact factor: 9.867

10.  SENP2 regulated the stability of β-catenin through WWOX in hepatocellular carcinoma cell.

Authors:  Qing-Feng Jiang; Yu-Wei Tian; Quan Shen; Huan-Zhou Xue; Ke Li
Journal:  Tumour Biol       Date:  2014-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.